GlassScriptPhysician profile
Shujauddin Mohammed
NPI 1811092794
$3,649.92
in general payments reported to CMS, 2019-2025
27 companies · $784 in 2025
The $784 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $276 · 2021: $374 · 2022: $469 · 2023: $809 · 2024: $723 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $545.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $476.14 | 2019-2025 | Farxiga |
| Abbott Laboratories | $391.04 | 2020-2025 | Gallant, Cardiomems |
| Merck Sharp & Dohme LLC | $371.68 | 2021-2025 | Verquvo, Lagevrio |
| Novo Nordisk INC | $246.24 | 2022-2025 | Wegovy, Ozempic |
| Amgen INC. | $228.64 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $190.30 | 2021-2025 | Bodyguardian, Watchman Flx, Vigilant X4 Crt-D |
| Janssen Pharmaceuticals, INC | $166.53 | 2022-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.99 | 2023-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $108.66 | 2025 | Assure Wcd |
| Canon Medical Systems USA, INC. | $98.85 | 2023 | Pet-Ct Scanner |
| Actelion Pharmaceuticals US, INC. | $96.01 | 2022 | |
| Esperion Therapeutics, INC. | $74.31 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $73.47 | 2022-2025 | Camzyos |
| Biosense Webster, INC. | $66.38 | 2025 | Carto 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $65.48 | 2019-2023 | Mounjaro |
| Lexicon Pharmaceuticals, INC. | $56.38 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.28 | 2023-2025 | Jardiance |
| Medtronic, INC. | $42.88 | 2022-2024 | Evera Mri Xt Dr Surescan |
| Inspire Medical Systems, INC. | $41.18 | 2024-2025 | Inspire |
| Pfizer INC. | $37.92 | 2022-2024 | |
| Bridgebio Pharma, INC. | $26.64 | 2025 | Attruby |
| Cvrx, INC. | $26.14 | 2024 | Barostim Neo System |
| Angiodynamics, INC. | $17.55 | 2020 | |
| Medtronic Vascular, INC. | $16.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.42 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shujauddin Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.